Evidence map›Paper›PMID 41737493›Full record

ArticleRSC advances2026

Development of dual acting selenium-doped hydroxyapatite nanoparticles with platinum-bisphosphonate complexes for bone cancer therapy.

Alessandra Barbanente, Anna Maria Di Cosola, Federica Rizzi, Nicoletta Depalo, Roberto Comparelli, Rachele Castaldo, Elisabetta Fanizza, Paride Papadia, Concetta Pacifico, Mauro Niso and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Alessandra BarbanenteDepartment of Chemistry, University of Bari Aldo Moro via E. Orabona 4 70126 Bari Italy nicola.margiotta@uniba.it.
Anna Maria Di CosolaDepartment of Chemistry, University of Bari Aldo Moro via E. Orabona 4 70126 Bari Italy nicola.margiotta@uniba.it.
Federica RizziInstitute for Chemical and Physical Processes (IPCF)-CNR SS Bari via Orabona 4 Bari 70126 Italy.
Nicoletta DepaloInstitute for Chemical and Physical Processes (IPCF)-CNR SS Bari via Orabona 4 Bari 70126 Italy.ORCID https://orcid.org/0000-0002-2107-2762
Roberto ComparelliInstitute for Chemical and Physical Processes (IPCF)-CNR SS Bari via Orabona 4 Bari 70126 Italy.ORCID https://orcid.org/0000-0003-4640-7204
Rachele CastaldoInstitute of Polymers, Composites and Biomaterials (IPCB)-CNR via Campi Flegrei 34 80078 Pozzuoli Naples Italy.
Elisabetta FanizzaDepartment of Chemistry, University of Bari Aldo Moro via E. Orabona 4 70126 Bari Italy nicola.margiotta@uniba.it.ORCID https://orcid.org/0000-0001-6293-9388
Paride PapadiaDepartment of Biological and Environmental Sciences and Technologies (DiSTeBA), University of Salento 73100 Lecce Italy.ORCID https://orcid.org/0000-0001-9611-3824
Concetta PacificoDepartment of Chemistry, University of Bari Aldo Moro via E. Orabona 4 70126 Bari Italy nicola.margiotta@uniba.it.ORCID https://orcid.org/0000-0001-6642-8083
Mauro NisoDepartment of Pharmacy-Pharmaceutical Sciences, University of Bari Aldo Moro via Orabona 4 70126 Bari Italy.
Nicola MargiottaDepartment of Chemistry, University of Bari Aldo Moro via E. Orabona 4 70126 Bari Italy nicola.margiotta@uniba.it.ORCID https://orcid.org/0000-0003-4034-875X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bone represents one of the most common sites for metastasis originating from solid tumors, especially breast and prostate cancers, causing severe complications like pain, fractures, and impaired quality of life. Hydroxyapatite (HA) nanoparticles (NPs) have been considered as good candidates for bone-targeted drug delivery due to their biocompatibility and osteoconductivity. In this study, we developed selenium-doped hydroxyapatite (HASe) NPs with reduced selenium content (up to 2.40 wt%) with the aim of overcoming the toxicity issues associated with previously reported higher Se doping levels. The HA-based NPs were thoroughly characterized to evaluate their morphological, colloidal, and compositional features, supporting the effective incorporation of selenium (Se) within the HA structure.

Identifiers

PMID41737493
PMCPMC12928151

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.